The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Randomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy
Open accessAbstract
CONTEXT: Graves' orbitopathy (GO) is a potentially sight-threatening disease for which available medical therapy is not uniformly successful. Multiple case series suggest that rituximab (RTX) may be effective therapy for GO patients. OBJECTIVE: To determine the efficacy of RTX in GO. DESIGN: It is a prospective, randomized, double-masked, placebo-controlled trial. SETTING: The study was conducted at a large academic private practice. PATIENTS: Twenty five patients with active moderate to severe GO were enrolled, and 21 completed the study to the primary endpoint. INTERVENTIONS: Two RTX infusions (1000 mg each) or two saline infusions were given 2 weeks apart. MAIN OUTCOME MEASURES: The primary endpoint was a reduction in clinical activity score (CAS) assessed as a continuum and separately as improvement by ≥ 2 points at 24 weeks. Secondary endpoints included success and failure rates, proportions showing clinically significant improvement in proptosis, lid fissure width, diplopia score, lagophthalmos and disease severity, and changes in those parameters, orbital fat/ muscle volume and quality-of-life. RESULTS: The treatment groups were similar in all parameters at baseline. The last observation was carried forward if the patient discontinued prematurely. No differences were found in the proportions of patients showing CAS improvement at 24 weeks (25% placebo; 31% RTX, P = .75) or in CAS decrease from baseline to 24 or 52 weeks [mean 1.5 points (1.8 SD) placebo; 1.2 (2 SD) RTX at 24 weeks, P = .73]. Similarly, there were no differences between groups in any of the secondary endpoints at either 24 or 52 weeks. There were four adverse events (AE) in 3/12 placebo patients and 11 AE in 8/13 RTX-treated patients; 5/6 moderate or severe AE occurred in the RTX group. CONCLUSION: RTX offered no additional benefit over placebo to our patients with active and moderate to severe GO and carried with it non-negligible adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392 · cited 4×
“0.5 (-1;0.25) .69 QOL SF-12 physical at 24 weeks - median (IQR) 40.3 (38.5;52.1) 45.9 (43.6;50.8) .33 QOL SF-12 mental at 24 weeks - median (IQR) 46.1 (35.4;57.4) 52.8 (36.1;56.7) .91 QOL SF-12 physical at 52 weeks - median (IQR) 46.7 (41.1;53.6) 51.8 (49.8;55.5) .29 QOL SF-12 mental at 52 weeks - median (IQR) 49.4 (3…”
MethodInfluentialCross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., Bullinger, M., Kaasa, S., Leplege, A., Prieto, L., et al. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00109-7 · Cited by 2,907
Sackett, D. L. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90012-2 · Cited by 2,075
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Self-citationBahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0417 · Cited by 898
Self-citationSelenium and the Course of Mild Graves' Orbitopathy
Marcocci, C., Kahaly, G. J., Krassas, G. E., Bartalena, L., Prummel, M., Stahl, M., Altea, M. A., Nardi, M., Pitz, S., Boboridis, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012985 · Cited by 619
Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves’ Orbitopathy
Kahaly, G. J., Pitz, S., Hommel, G., & Dittmar, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0148 · Cited by 423
Bartalena, L., Baldeschi, L., Dickinson, A. J., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M. P., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · Thyroid · doi:10.1089/thy.2007.0315 · Cited by 406
Bartalena, L., Krassas, G. E., Wiersinga, W., Marcocci, C., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Veronesi, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2389 · Cited by 370
Tanda, M. L., Piantanida, E., Liparulo, L., Veronesi, G., Lai, A., Sassi, L., Pariani, N., Gallo, D., Azzolini, C., Ferrario, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3873 · Cited by 328
Perros, P., Crombie, A. L., Matthews, J. N. S., & Kendall‐Taylor, P. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb00516.x · Cited by 288
Salvi, M., Vannucchi, G., Campi, I., Currò, N., Dazzi, D., Simonetta, S., Bonara, P., Rossi, S., Sina, C., Guastella, C., et al. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02325 · Cited by 264
Gandek, Ware, Aaronson, & Apolone (1998) · Journal of Clinical Epidemiology · Cited by 225
Natural history of thyroid associated ophthalmopathy
Perros, P., Cromble, A. L., & Kendall‐Taylor, P. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02597.x · Cited by 219
Khanna, D., Chong, K. K. L., Afifiyan, N. F., Hwang, C. J., Lee, D. K., Garneau, H. C., Goldberg, R. A., Darwin, C. H., Smith, T. J., & Douglas, R. S. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.029 · Cited by 172
Sackett, D. L. (1979) · The Case-Control Study Consensus and Controversy · doi:10.1016/b978-0-08-024907-0.50013-4 · Cited by 169
Choice of Therapy and Criteria for Assessing Treatment Outcome in Thyroid-associated Ophthalmopathy
Bahn, R. S., & Gorman, C. A. (1987) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30485-7 · Cited by 159
Self-citationSalvi, M., Vannucchi, G. M., Campi, I., Rossi, S., Bonara, P., Sbrozzi, F., Guastella, C., Avignone, S., Pirola, G., Ratiglia, R., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02119 · Cited by 145
van Geest, R. J., Sasim, I. V., Koppeschaar, H. P. F., Kalmann, R., Stravers, S., Bijlsma, W. R., & Mourits, M. P. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0558 · Cited by 127
Fassi, D. E., Nielsen, C. H., Hasselbalch, H. C., & Hegedűs, L. D. (2006) · Thyroid · doi:10.1089/thy.2006.16.709 · Cited by 116
Spontaneous Improvement of Untreated Mild Graves' Ophthalmopathy: Rundle's Curve Revisited
Menconi, F., Profilo, M. A., Leo, M., Sisti, E., Altea, M. A., Rocchi, R., Latrofa, F., Nardi, M., Vitti, P., Marcocci, C., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0240 · Cited by 111
Effects of Graves’ ophthalmopathy on quality of life
Wiersinga, W. M., Prummel, M. F., & Terwee, C. B. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345275 · Cited by 97
Potential Utility of Rituximab for Graves' Orbitopathy
Salvi, M., Vannucchi, G. M., & Beck‐Peccoz, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1804 · Cited by 91
Dickinson, A. J., Vaidya, B., Miller, M. A., Coulthard, A., Perros, P., Baister, E. R., Andrews, C. D., Hesse, L., Heverhagen, J. T., Heufelder, A. E., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0697 · Cited by 90
Wémeau, J.-L., Caron, P. J., Beckers, A. M., Rohmer, V., Orgiazzi, J., Borson‐Chazot, F., Calzada-Nocaudie, M., Perimenis, P., Bisot-Locard, S., Bourdeix, I., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1334 · Cited by 83
Rituximab for Thyroid Eye Disease
Silkiss, R. Z., Reier, A., Coleman, M., & Lauer, S. A. (2010) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0b013e3181c4dfde · Cited by 81
Mitchell, A. L., Gan, E. H., Morris, M., Johnson, K., Neoh, C., Dickinson, A. J., Perros, P., & Pearce, S. H. S. (2013) · Clinical Endocrinology · doi:10.1111/cen.12141 · Cited by 79
Stan, M. N., Garrity, J. A., Bradley, E. A., Woog, J. J., Bahn, M. M., BRENNAN, M. D., Bryant, S. C., Achenbach, S. J., & Bahn, R. S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1105 · Cited by 65
Self-citationSalvi, M., Vannucchi, G. M., Campi, I., Currò, N., Simonetta, S., Covelli, D., Pignataro, L., Guastella, C., Rossi, S., Bonara, P., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2008.12.005 · Cited by 58
Burch, H. B., & Bahn, R. S. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00081-2 · Cited by 56
Self-citationFailure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids
Krassas, G. E., Stafilidou, A., & Boboridis, K. G. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03762.x · Cited by 53
Comparability of proptosis measurements by different techniques
Segni, M., Bartley, G. B., Garrity, J. A., Bergstralh, E. J., & Gorman, C. A. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01429-0 · Cited by 53
Self-citationChang, T., & Liao, S. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344124 · Cited by 48
Madaschi, S., Rossini, A., Formenti, I., Lampasona, V., Marzoli, S. B., Cammarata, G., Politi, L. S., Martinelli, V., Bazzigaluppi, E., Scavini, M., et al. (2010) · Endocrine Practice · doi:10.4158/ep09385.ra · Cited by 24
Cited by
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Teprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Douglas, R. S., Kahaly, G. J., Patel, A., Sile, S., Thompson, E. H. Z., Perdok, R., Fleming, J. C., Fowler, B. T., Marcocci, C., Marinò, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910434 · Cited by 752
Metadata
- Authors
- Stan, M. N., Garrity, J. A., Carranza Leon, B. G., Prabin, T., Bradley, E. A., & Bahn, R. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 432-441
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2158064334
- Cited by
- 369
- References
- 36
- FWCI
- 15.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.